In the Phase 3 trials, SKYLIGHT 1, 2, and 4, elevations in hepatic transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) > 3 × upper limit of normal (ULN) occurred in 2.3% of women receiving fezolinetant 45 mg and 0.9% of women receiving placebo
VEOZAH [package insert]. Northbrook, IL, USA: Astellas Pharma, Inc. Available at: https://www.astellas.com/us/system/files/veozah_uspi.pdf.
Kagan R, Cano A, Nappi RE, et al. Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. Adv Ther. 2024. https://dx.doi.org/10.1007/s12325-024-03073-8.
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here